- Muñoz-Hernández, Rocío
- Gato, Sheila
- Gil-Gómez, Antonio
- Aller, Rocío
- Rojas, Ángela
- Morán, Laura
- Gallego, Javier
- Blázquez-López, Elena
- Gallego-Durán, Rocío
- Montero-Vallejo, Rocío
- García-Fernández, Vanessa
- Maya-Miles, Douglas
- Rico, María Carmen
- Cubero, Francisco Javier
- Vaquero, Javier
- Ampuero, Javier
- Bañares, Rafael
- Romero-Gómez, Manuel
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background and Aims] Extracellular vesicles (EVs) have emerged as a potential source of circulating biomarkers in liver disease. We evaluated circulating AV+ EpCAM+ CD133+ EVs as a potential biomarker of the transition from simple steatosis to steatohepatitis., [Methods] EpCAM and CD133 liver proteins and EpCAM+ CD133+ EVs levels were analysed in 31 C57BL/6J mice fed with a chow or high fat, high cholesterol and carbohydrates diet (HFHCC) for 52 weeks. The hepatic origin of MVs was addressed using AlbCrexmT/mG mice fed a Western (WD) or Dual diet for 23 weeks. Besides, we assessed plasma MVs in 130 biopsy-proven NAFLD patients., [Results] Hepatic expression of EpCAM and CD133 and EpCAM+ CD133+ EVs increased during disease progression in HFHCC mice. GFP+ MVs were higher in AlbCrexmT/mG mice fed a WD (5.2% vs 12.1%) or a Dual diet (0.5% vs 7.3%). Most GFP+ MVs were also positive for EpCAM and CD133 (98.3% and 92.9% respectively), suggesting their hepatic origin. In 71 biopsy-proven NAFLD patients, EpCAM+ CD133+ EVs were significantly higher in those with steatohepatitis compare to those with simple steatosis (286.4 ± 61.9 vs 758.4 ± 82.3; p < 0.001). Patients with ballooning 367 ± 40.6 vs 532.0 ± 45.1; p = 0.01 and lobular inflammation (321.1 ± 74.1 vs 721.4 ± 80.1; p = 0.001), showed higher levels of these EVs. These findings were replicated in an independent cohort., [Conclusions] Circulating levels of EpCAM+ CD133+ MVs in clinical and experimental NAFLD were increased in the presence of steatohepatitis, showing high potential as a non-invasive biomarker for the evaluation and management of these patients., This work was supported by Consejería de Salud y Familias (PI-0039-2017 to RM), Sociedad Andaluza de Patología Digestiva (Beca Dr. Gonzalo Miño Fugarolas to RM), Talento Doctores (PID Junta Andalucía, DOC_00866, to RM), Consejería Economía, Conocimiento, Empresas y Universidad, Proyecto P20_01075 de financiación pública en la convocatoria 2020 en la modalidad Ayudas a proyectos de I+D+i, destinadas a las universidades y entidades públicas de investigación calificadas como agentes del Sistema Andaluz del Conocimiento, en el ámbito del Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI 2020). Convocatoria financiada con Fondo Europeo de Desarrollo Regional (FEDER) al 80%. Andalucía se mueve con Europa to MR. Instituto de Salud Carlos III to MR/RM (PI19/00589), to MR (PMP21/00078) and PI22/01342 to MR, PFIS FI20/00201 to SG, Consejería de Salud y Familias, Junta de Andalucía to AGG (RH-122-2020) and AR (RH-002-2021), i-PFIS 18/00041 to RM, Sara Borrel CD21-00095 to RGD and Comunidad de Madrid y Fondos FEDER ‘Una manera de hacer Europa’, S2017/BMD3727, ExoHep-CM to RB., Peer reviewed